Jonathan L. Halperin, M.D., is an American cardiologist and the author of Bypass (ISBN 0895865092), among the most comprehensive works on the subject of coronary artery bypass surgery. In addition, he is the Robert and Harriet Heilbrunn Professor of Medicine at The Mount Sinai School of Medicine as well as Director of Clinical Cardiology in the Zena and Michael A. Wierner Cardiovascular Institute at The Mount Sinai Medical Center, both in New York City.

Halperin's clinical investigations have included studies of cardiovascular hemodynamics that contribute to the development of angiotensin converting enzyme inhibition for patients with chronic congestive heart failure, as well as studies of regional circulation that impact the management of patients with Raynaud's disease, mitral valve disease, and intermittent claudication. Halperin was the principal cardiologist responsible for both the design and execution of the multi-center Stroke Prevention in Atrial Fibrillation (SPAF) clinical trials, funded by the National Institutes of Health, which helped develop antithrombotic strategies to prevent stroke, and he subsequently directed the SPORTIF clinical trials, which evaluated the first oral direct thrombin inhibitor for prevention of stroke in patients with atrial fibrillation.

Halperin is the author of 3 books, 80 original peer reviewed reports, 38 chapters, 24 guidelines and position statements, 51 invited articles and 58 abstracts. He is listed among New York Magazine’s Best Doctors of 2009.

This author page uses material from the Wikipedia article "Jonathan L. Halperin", which is released under the Creative Commons Attribution-Share-Alike License 3.0